NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
NEW YORK, May 04, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held on Tuesday, May 8, 2018 at 8:30am ET to discuss results for the first quarter of 2018 and provide a business outlook for the remainder of the year. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2018 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Jenna Bosco
SVP, Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: [email protected]
